

Citrullinemic Lymphocytes in Long Term Culture

E. B. SPECTOR^[17] AND A. D. BLOOM

Department of Human Genetics, University of Michigan Medical School, Ann Arbor, Michigan, USA

Extract

Peripheral blood lymphocytes from a 33-year-old male with citrullinemia were established in long term, continuous culture. This lymphocyte line was designated UM-21 (University of Michigan, lymphoid line no. 21), and the behavior of the cells of this line was studied under selective conditions *in vitro*. When arginine was removed from the medium and replaced with citrulline, the UM-21 lymphocytes were unable to enter logarithmic growth phase. This contrasted with lymphocyte lines from normal donors which were able to utilize the citrulline readily and to grow logarithmically. We interpreted this as presumptive evidence that, unlike normal lymphocytes, the citrullinemic lymphocytes were deficient in argininosuccinic acid synthetase (AS). Despite the initial inability of the citrullinemic lymphocytes to grow logarithmically in a medium with 200 mg/liter citrulline substituted for the normally used arginine (Cit⁺, Arg⁻ medium), after 4 weeks of continuous incubation some cells did begin to divide and a variant of the UM-21 line was subsequently established.

Cells from the parental UM-21 line, the variant line, and two normal lymphocyte lines were incubated with ureido-¹⁴C-citrulline to determine their relative uptake and incorporation of citrulline. On autoradiography, the UM-21 cells showed no label. Cells from the variant line showed a diverse labeling pattern: 11.7% of cells were heavily labeled, 32.4% were lightly labeled, and 55.9% showed no label. The cells from the normal donors were uniformly heavily labeled. Further, the incorporation of label into trichloroacetic acid-precipitable cellular material was examined. UM-21 incorporated 360 cpm, the variant line 1,951 cpm, and the two normal lines 2,544 and 2,427 cpm, respectively. The counts per minute are here expressed per 10⁵ cells, or 3.3-3.5 × 10⁻³ mg protein.

Speculation

Although a more sensitive assay for AS will have to be developed for lymphocyte lines, it is apparent from the data presented here that the citrullinemic defect is expressed in cultured lymphocytes under proper selective conditions. The basic defect in this disease is likely to be either a regulatory or structural gene mutation, and the variant line may represent a reverse mutation. It may prove possible to study each of the four known genetically determined disorders of urea metabolism by use of the cultured lymphocyte.

Introduction

Citrullinemia is one of four amino acidurias associated with the Krebs-Henseleit urea cycle (Fig. 1). The disease is thought to be due to a deficiency of the normal

liver enzyme argininosuccinate synthetase (AS), which catalyzes the conversion of citrulline plus aspartate to argininosuccinic acid [10]. Although the degree of mental retardation is variable in this disease, the levels




Fig. 1. The Krebs-Henseleit urea cycle. The block at I results from ornithine transcarbamylase deficiency; at II, the argininosuccinic acid synthetase defect results in citrullinemia; at III, argininosuccinase deficiency results in argininosuccinic aciduria; and at IV, lysine intolerance results, apparently from an inhibition of arginase activity.

of citrulline in serum, urine, and cerebrospinal fluid are usually elevated [4-6]. Patients with citrullinemia have sporadic episodes of convulsions which are presumed to be associated with ammonia intoxication, despite the fact that the levels of arginine and ornithine as well as the production of urea are often normal.

The particular patient from whom we established this first citrullinemic lymphocyte line was a 33-year-old mentally retarded male, described in detail by Scott-Emuakpor *et al.* [8]. This patient differed from the patients with citrullinemia described earlier [4, 6] in that he had a reasonably efficient ammonia removal mechanism. Our interest in establishing his lymphocytes in long term culture was, first, to determine whether or not the citrullinemic defect was expressed in cultured lymphoblasts, and, second, to determine whether his cells were genetically homogeneous in their inability to utilize citrulline.

Methods and Materials

Lymphocyte Lines

The continuously propagated lymphocyte lines used in this study were established by the lysate method, described originally by Choi and Bloom [2]. The cell lysate used contains the Epstein-Barr virus which is thought to play a role in the establishment and continuous propagation of the cell lines. To date, no effect of the viral genome on the metabolic function of the host cells has been found. Cell line UM-10 was established in April 1970 from a 10-year-old male with the Lesch-Nyhan syndrome. Cell line UM-21 was established in July 1970 from the patient with citrullinemia described above. Cell line UM-43 was derived from a normal 22-year-old male and has been in continuous culture since January 1971. Each line has a modal chromosome number of 46, with an XY chromosome constitution.

Growth Medium

Lymphocytes were maintained in Roswell Park Memorial Institute medium (RPMI) 1640 with 20% fetal calf serum, penicillin, and streptomycin. This medium normally contains 200 mg/liter arginine. For the growth experiments, 0.3×10^6 cells/ml were grown in three types of media: RPMI with 200 mg/liter arginine (Cit⁻, Arg⁺); RPMI with 200 mg/liter citrulline substituted for arginine (Cit⁺, Arg⁻); and RPMI without citrulline or arginine (Cit⁻, Arg⁻). Total cells were counted every 48 hr in a hemacytometer, and

viability was determined by trypan blue dye exclusion [11].

Autoradiography

Cells from UM-10 and UM-21 (parent and variant) were used in this experiment. We incubated 5×10^5 logarithmically growing cells for 48 hr in medium containing 1 μ Ci/ml ureido-¹⁴C-citrulline (sp act 3.73 mCi/mM [12]). The cells were washed three times with Hanks' balanced salt solution and centrifuged at 1,000 rpm. They were then resuspended in fetal calf serum, placed on slides, and dipped in Kodak NTB-3 emulsion. After 5 days of exposure, the slides were developed in D-19 for 3 min.

¹⁴C-Citrulline Incorporation into Cellular Protein

Cells (5×10^5) from each line were inoculated into each of three test tubes in 4 ml medium containing no citrulline, arginine, or fetal calf serum and incubated for 12 hr at 37°. This medium was then replaced with an equal volume of medium containing 175 mg/liter cold citrulline and 1 μ Ci/ml ureido-¹⁴C-citrulline (sp act 3.73 mCi/mM [12]). The cells were incubated in this medium for an additional 12 hr. The cells were then pipetted into a filter apparatus containing glass fiber filter paper [13]. They were then washed successively with approximately 40 ml each 0.85% saline, 5% cold trichloroacetic acid, and absolute methanol. The filter papers were allowed to air dry and then placed in scintillation vials with 0.5 ml Soluene [14] and incubated at 37° overnight. The counts per minute in the trichloroacetic acid precipitate were determined in a Packard Tri-Carb scintillation counter model 3320 [14].

Milligrams of protein were determined by a modification of the Lowry method [3].

Determination of Doubling Times

Cultures for estimation of the population doubling times were initiated with 0.3×10^6 cells/ml. The UM-21 cells were placed in Cit⁻, Arg⁺ medium. The UM-21 variant (capable of growing in citrulline) was inoculated into Cit⁺, Arg⁻ medium. The UM-10 cell line was studied in both Cit⁻, Arg⁺ and Cit⁺, Arg⁻ medium. The cell count was determined at 24-hr intervals with a hemacytometer, and the doubling times were calculated by the method of Aoki and Moore [1].

Assay for Argininosuccinate Synthetase

Lines UM-10, UM-21, and UM-43 were assayed by Dr. P. Snodgrass using a spectrophotometric assay first

described by R. T. Schimke [7]. Packed cells (0.4 ml) were used in the determinations. UM-10 contained 8.77 mg protein/ml, UM-21 contained 15.0 mg protein/ml, and UM-43 contained 8.75 mg of protein/ml.

Results

Growth Curves

The results are presented in Fig. 2. The UM-10, UM-43, and UM-21 cells grown in RPMI 1640 Cit⁻, Arg⁺ showed normal logarithmic growth and reached a maximum live cell density of 1×10^6 cells/ml before being subcultured. The UM-10 and UM-43 cells grown




Fig. 2. Growth of "normal" (UM-10) and citrullinemic (UM-21) lymphocytes in medium which contains no arginine and 20 mg/100 ml citrulline (Cit⁺, Arg⁻) or in medium which contains no citrulline or arginine (Cit⁻, Arg⁻). Inoculations of 0.3×10^6 cells/ml were made into each of the two types of media. The total number of viable cells was determined every 48 hr with trypan blue dye exclusion. The UM-10 cells in Cit⁺, Arg⁻ medium are represented by \circ — \circ , the UM-10 cells in Cit⁻, Arg⁻ medium by \bullet — \bullet , the UM-21 cells in Cit⁺, Arg⁻ medium by \triangle — \triangle , and the UM-21 cells in Cit⁻, Arg⁻ medium by \blacktriangle — \blacktriangle .

in Arg⁻, Cit⁻ medium died within 6 days, whereas UM-21 cells could be maintained for a month in this medium before senescence. The UM-10 and UM-43 cells grown in Cit⁺, Arg⁻ medium also showed normal logarithmic growth, whereas UM-21 cells failed to grow in this medium. However, most of the UM-21 cells did remain viable, and the concentration of cells in the original population (0.2×10^6 cells/ml) was maintained for 3–4 weeks. These cells were incubated continuously thereafter in Cit⁺, Arg⁻ medium, and after a month the cells began to increase in number. Those cells which were able to grow in the presence of citrulline constitute a population of cells different from the parental line and are referred to as the UM-21 variant cells. They were maintained in Cit⁺, Arg⁻ RPMI 1640 medium. Nine clones of the parental UM-21 line are now being studied.

Doubling Times

The UM-10 cells in Cit⁺, Arg⁻ RPMI 1640 doubled in 24.6 hr, whereas the UM-21 variant cells failed to enter logarithmic growth phase. However, UM-10 and UM-21 in Cit⁻, Arg⁺ medium had doubling times of 23.8 and 27.3 hr, respectively. Thus, there was no significant difference between the doubling times of cells from UM-10 that had been growing in medium containing citrulline or in medium containing arginine. The UM-21 cells grown in medium containing arginine had a doubling time similar to that of the UM-10 cells. However, the UM-21 variant cells that had been incubated in medium with citrulline doubled only once in 6 days.

Autoradiography

Cells from UM-10 were labeled heavily and uniformly with ¹⁴C while cells from UM-21 showed no label at all (Fig. 3). The UM-21 variant cells showed a diverse labeling pattern: 11.7% of cells were labeled heavily (more than 20 grains/cell), similar to the UM-10 cells; 32.4% of cells were lightly labeled (11–20 grains per cell), *i.e.*, they had incorporated some label but not as much as the UM-10 cells; and 55.9% of cells had incorporated essentially no label (less than 10 grains), as was the case for the UM-21 cells.

¹⁴C-Citrulline Incorporation

When cells were incubated for 12 hr with labeled citrulline, the precipitate from the UM-43 cells had 2,544 cpm; that from UM-10 cells, 2,427 cpm; that from UM-21, 360 cpm; and that from UM-21 variant cells, 1,951 cpm. The counts per minute are expressed




Fig. 3. Autoradiography of "normal" (UM-10) and citrullinemic (UM-21) lymphocytes with ureido- ^{14}C -citrulline. We incubated 0.5×10^5 cells for 48 hr with $1 \mu\text{Ci/ml}$ label. *A*: Heavy labeling found in the UM-10 cells; *B*: complete absence of label in a UM-21 cell.

per 10^5 cells, which is equivalent to $3.3\text{--}3.5 \times 10^{-3}$ mg protein.

The mean counts per minute of the four samples were compared using Duncan's new multiple range test [9]. There is no significant difference ($P < 0.01$) between the mean counts of UM-10, UM-43, and UM-21 variant, but the means of these three samples do differ significantly ($P < 0.01$) from the mean counts of UM-21.

Direct Enzyme Assay

No AS was detectable in any of the three lines tested, UM-43, UM-21, and UM-10, which indicates that the level of this enzyme in lymphocyte lines from citrullinemic and noncitrullinemic donors is very low. In the future, a more sensitive radioactive assay for AS will have to be used.

Discussion

Despite the fact that AS was not detectable spectrophotometrically in the lymphocyte lines used in this study, we have considerable indirect evidence here for the expression of this enzyme in lymphocytes established from "normal" donors, and for its lack of expression in UM-21, the citrullinemic cell line. Cells from UM-21 were unable to enter logarithmic growth in medium in which citrulline had been substituted for arginine. These cells also showed a reduced uptake of la-

beled ^{14}C -citrulline on autoradiography and a markedly reduced incorporation of labeled citrulline into trichloroacetic acid-precipitable cellular protein.

Our isolation of a metabolic variant of UM-21 may have direct relevance to the clinical situation in this patient. The cells of the variant line showed a heterogeneous labeling pattern but incorporated ^{14}C -citrulline into cellular protein almost as efficiently as the normal lymphocytes. These findings suggest that some cells from within this citrullinemic patient may have normal or nearly normal citrulline metabolism. Metabolic cooperation between normal and deficient cells might account for the seeming ease with which the patient disposes of ammonia and excretes normal amounts of urea.

Alternatively, and more likely, the variant line could be derived from a back mutation that occurred *in vitro* during the 2 years that the cells have been in culture. These "normal" or revertant cells might then have been selected for when the UM-21 cells were grown in Cit^+ , Arg^- medium. The variant line may be comprised of cells with normal activity or of cells with partial activity that survive in selective medium through metabolic cooperation. The fact that the variant line had to be subcultured at a high population density for growth to occur suggests, however, that these cells do not have normal enzyme activity.

The basic defect in citrullinemia is not yet known, although the studies of Tedesco and Mellman [10] on

citrullinemic fibroblasts suggest a structural gene mutation. They found that the AS in citrullinemic fibroblasts has an increased K_m for its substrate, and concluded that a structurally altered enzyme would be compatible with the reduced ability of the cells to utilize citrulline.

Summary

Peripheral blood lymphocytes were obtained from a patient with citrullinemia and established in continuous culture. These cells were unable to utilize citrulline in the growth medium and failed to incorporate ureido- ^{14}C -citrulline into cellular protein, which suggests either that they were defective in argininosuccinate synthetase or that they have a primary defect in citrulline transport. Under selective conditions, a variant line arose, which represented either a back mutation or a second *in vivo* cell population.

Addendum

Assay for argininosuccinate synthetase was recently performed on cell lines UM-43 and UM-21 by Dr. Nancy Kennaway, Department of Pediatrics, University of Oregon Medical School, using a modification of the Schimke method [7]. Dr. Kennaway found the specific activity for the synthetase in UM-43 to be 0.059 $\mu\text{mol}/\text{mg}$ protein/hr, while the UM-21 parent line had no detectable activity, which confirms the absence of catalytically active synthetase in the cells of this citrullinemic patient.

References and Notes

1. AOKI, Y., AND MOORE, G. E.: Comparative study of mitotic stages of cells derived from human peripheral blood. *Exp. Cell Res.*, **59**: 259 (1970).
2. CHOI, K. W., AND BLOOM, A. D.: Cloning human lymphocytes *in vitro*. *Nature*, **227**: 171 (1970).
3. LOWRY, O. H., ROSEBROUGH, N. J., FARR, A. L., AND RANDALL, R. J.: Protein measurement with the Folin phenol reagent. *J. Biol. Chem.*, **193**: 265 (1951).
4. McMURRAY, W. C., RATHBUN, J. C., MOHYUDDIN, F., AND KOEGLER, S. J.: Citrullinemia. *Pediatrics*, **32**: 347 (1963).
5. MOHYUDDIN, F., RATHBUN, J. C., AND McMURRAY, W. C.: Studies on amino acid metabolism in citrullinuria. *Amer. J. Dis. Child.*, **113**: 152 (1967).
6. MORROW, G., BARNES, L. A., AND EFRON, M. L.: Citrullinemia with defective urea production. *Pediatrics*, **40**: 565 (1967).
7. SCHIMKE, R. T.: Enzymes of arginine metabolism in mammalian cell culture. I. Repression of argininosuccinic synthetase and argininosuccinase. *J. Biol. Chem.*, **239**: 136 (1964).
8. SCOTT-EMUAKPOR, A., HIGGINS, J. V., AND KOHRMAN, A. F.: Citrullinemia: A new case, with implications concerning adaptation to defective urea synthesis. *Pediat. Res.*, **6**: 626 (1972).
9. STEEL, R. G. D., AND TORRIE, J. H.: Principles and Procedures of Statistics, p. 107. (McGraw-Hill, New York, 1960).
10. TEDESCO, T. A., AND MELLMAN, W. J.: Argininosuccinate synthetase activity and citrulline metabolism in cells cultured from a citrullinemic subject. *Proc. Nat. Acad. Sci. U. S. A.*, **57**: 829 (1967).
11. TENNANT, J. R.: Evaluation of the trypan blue technique for determination of cell viability. *Transplantation*, **2**: 685 (1964).
12. New England Nuclear Corporation, Boston, Mass.
13. GF/A, Whatman-Reeve Angel, Clifton, N. J.
14. Packard Instrument Company, Downer's Grove, Ill.
15. We thank Dr. J. V. Higgins for obtaining peripheral blood from the patient described in Reference 8.
16. This research was supported by National Institutes of Health Program Project Grant no. 5-T01-GM-71-15, National Institute of General Medical Sciences, and National Institutes of Health Training Grant in Genetics 0-10-141.
17. Requests for reprints should be addressed to: ELAINE B. SPECTOR, Department of Human Genetics, School of Medicine, University of Michigan, Ann Arbor, Mich. 48104 (USA).
18. Accepted for publication March 13, 1973.